Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants

Microbial Drug Resistance

Volumn 17, Issue 3, 2011, Pages 363-367

  Yang, Jiyong ^a   Luo, Yanping ^a   Cui, Shenghui ^b   Wang, Weiwei ^c   Han, Li ^c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Food and Drug Administration   (China)

^c Center for Hospital Infection Control   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAMASE DHA; BETA LACTAMASE OXA 1; BETA LACTAMASE SHV; BETA LACTAMASE TEM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PROTEIN PARC; PROTEIN QNRB; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CHROMOSOME; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; ESCHERICHIA COLI; GENE MUTATION; GENOTYPE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; PLASMID; PREVALENCE; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MUTATION; PLASMIDS; QUINOLONES;

ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE;

EID: 80052228172     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2011.0034     Document Type: Article

References (26)

1. Allou N., E. Cambau, L. Massias, F. Chau, and B. Fantin. 2009. Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. Antimicrob. Agents Chemother. 53:4292-4297.
2. Cattoir V., and P. Nordmann. 2009. Plasmid-mediated quinolone resistance in gram-negative bacterial species: An update. Curr. Med. Chem. 16:1028-1046.
3. Cattoir V., L. Poirel, V. Rotimi, C.J. Soussy, and P. Nordmann. 2007. Multiplex PCR for detection of plasmidmediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J. Antimicrob. Chemother. 60:394-397. (Pubitemid 47243891)
4. Cesaro A., R.R. Bettoni, C. Lascols, A. Merens, C.J. Soussy, and E. Cambau. 2008. Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmidborne qnr genes. J. Antimicrob. Chemother. 61:1007-1015. (Pubitemid 351524440)
5. CLSI. 2009. Performance Standards for Antimicrobial Susceptibility Testing, 19th Informational Supplement (M100- S19), Vol. 29, No. 3. CLSI 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.
6. Dallenne C., A. Da Costa, D. Decre, C. Favier, and G. Arlet. 2010. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J. Antimicrob. Chemother. 65:490-495.
7. Everett M.J., Y.F. Jin, V. Ricci, and L.J. Piddock. 1996. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother. 40:2380-2386. (Pubitemid 26328050)
8. Hussein K., H. Sprecher, T. Mashiach, I. Oren, L. Kassis, and R. Finkelstein. 2009. Carbapenem resistance among Klebsiella pneumoniae isolates: Risk factors, molecular characteristics, and susceptibility patterns. Infect. Control Hosp. Epidemiol. 30:666-671.
9. Jones C.H., M. Tuckman, D. Keeney, A. Ruzin, and P.A. Bradford. 2009. Characterization and sequence analysis of extended-spectrum-{beta}-lactamase- encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. Antimicrob. Agents Chemother. 53:465-475.
10. Lascols C., J. Robert, V. Cattoir, C. Bebear, J.D. Cavallo, I. Podglajen, M.C. Ploy, R. Bonnet, C.J. Soussy, and E. Cambau. 2007. Type II topoisomerase mutations in clinical isolates of Enterobacter cloacae and other enterobacterial species harbouring the qnrA gene. Int. J. Antimicrob. Agents 29:402-409. (Pubitemid 46357607)
11. Leinberger D.M., V. Grimm, M. Rubtsova, J. Weile, K. Schroppel, T.A. Wichelhaus, C. Knabbe, R.D. Schmid, and T.T. Bachmann. 2010. Integrated detection of extendedspectrum- beta-lactam resistance by DNA microarray-based genotyping of TEM, SHV, and CTX-M genes. J. Clin. Microbiol. 48:460-471.
12. Li X.Z., and H. Nikaido. 2009. Efflux-mediated drug resistance in bacteria: An update. Drugs 69:1555-623.
13. Mammeri H., L. Poirel, and P. Nordmann. 2005. Bactericidal activity of fluoroquinolones against plasmid-mediated QnrA-producing Escherichia coli. Clin. Microbiol. Infect. 11:1048-1049. (Pubitemid 41748944)
14. Morgan-Linnell S.K., L. Becnel Boyd, D. Steffen, and L. Zechiedrich. 2009. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 53:235-241.
15. Pai H., M.R. Seo, and T.Y. Choi 2007. Association of QnrB determinants and production of extended-spectrum betalactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 51:366-368. (Pubitemid 46047732)
16. Park C.H., A. Robicsek, G.A. Jacoby, D. Sahm, and D.C. Hooper. 2006. Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin- modifying enzyme. Antimicrob. Agents Chemother. 50:3953-3955. (Pubitemid 44684926)
17. Ribot E.M., M.A. Fair, R. Gautom, D.N. Cameron, S.B. Hunter, B. Swaminathan, and T.J. Barrett 2006. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157:H7, Salmonella, and Shigella for PulseNet. Foodborne Pathog. Dis. 3:59-67.
18. Robberts F.J., P.C. Kohner, and R. Patel. 2009. Unreliable extended-spectrum beta-lactamase detection in the presence of plasmid-mediated AmpC in Escherichia coli clinical isolates. J. Clin. Microbiol. 47:358-361.
19. Rodriguez-Bano J., and M.D.Navarro 2008. Extendedspectrum beta-lactamases in ambulatory care: A clinical perspective. Clin. Microbiol. Infect. 14 Suppl 1:104-110. (Pubitemid 350284181)
20. Rodriguez-Bano J., and A. Pascual 2008. Clinical significance of extended-spectrum beta-lactamases. Expert Rev. Anti. Infect. Ther. 6:671-683.
21. Rodriguez-Martinez J.M., C. Velasco, I. Garcia, M.E. Cano, L. Martinez-Martinez, and A. Pascual. 2007. Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1. Antimicrob. Agents Chemother. 51:2236-2239. (Pubitemid 46903126)
22. Strahilevitz J., G.A. Jacoby, D.C. Hooper, and A. Robicsek 2009. Plasmid-mediated quinolone resistance: A multifaceted threat. Clin. Microbiol. Rev. 22:664-689.
23. Tran J.H., G.A. Jacoby, and D.C. Hooper. 2005. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob. Agents Chemother. 49:118-125. (Pubitemid 40065781)
24. Tran J.H., G.A. Jacoby, and D.C. Hooper. 2005. Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob. Agents Chemother. 49:3050-3052. (Pubitemid 40917639)
25. Wang H., M. Chen, Y. Ni, Y. Liu, H. Sun, Y. Yu, X. Yu, Y. Mei, M. Liu, Z. Sun, et al. 2010. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. Int. J. Antimicrob. Agents 35:227-234.
26. Zahar J.R., O. Lortholary, C.Martin, G. Potel, P. Plesiat, and P. Nordmann. 2009. Addressing the challenge of extendedspectrum beta-lactamases. Curr. Opin. Investig. Drugs 10: 172-180.